<?xml version="1.0" encoding="ASCII"?>
<biogps><data><item key="owner">ArrayExpress Uploader</item><item key="pop_total">0</item><item key="id">2674</item><item key="factors"><item><item key="GSM969469"><item key="TREATMENT PROTOCOL">in the presence of DHT</item><item key="CELL LINE">LNCaP prostate cancer cells</item><item key="VARIATION">depleted of EZH2</item></item></item><item><item key="GSM969468"><item key="TREATMENT PROTOCOL">in the presence of DHT</item><item key="CELL LINE">LNCaP prostate cancer cells</item><item key="VARIATION">transfected with control siRNA</item></item></item><item><item key="GSM969469"><item key="TREATMENT PROTOCOL">in the presence of DHT</item><item key="CELL LINE">LNCaP prostate cancer cells</item><item key="VARIATION">depleted of EZH2</item></item></item><item><item key="GSM969468"><item key="TREATMENT PROTOCOL">in the presence of DHT</item><item key="CELL LINE">LNCaP prostate cancer cells</item><item key="VARIATION">transfected with control siRNA</item></item></item><item><item key="GSM969469"><item key="TREATMENT PROTOCOL">in the presence of DHT</item><item key="CELL LINE">LNCaP prostate cancer cells</item><item key="VARIATION">depleted of EZH2</item></item></item><item><item key="GSM969468"><item key="TREATMENT PROTOCOL">in the presence of DHT</item><item key="CELL LINE">LNCaP prostate cancer cells</item><item key="VARIATION">transfected with control siRNA</item></item></item><item><item key="GSM969463"><item key="TREATMENT PROTOCOL">under hormone depleted conditions</item><item key="CELL LINE">LNCaP-abl (abl) prostate cancer cells</item><item key="VARIATION">depleted of EZH2</item></item></item><item><item key="GSM969462"><item key="TREATMENT PROTOCOL">under hormone depleted conditions</item><item key="CELL LINE">LNCaP-abl (abl) prostate cancer cells</item><item key="VARIATION">transfected with control siRNA</item></item></item><item><item key="GSM969463"><item key="TREATMENT PROTOCOL">under hormone depleted conditions</item><item key="CELL LINE">LNCaP-abl (abl) prostate cancer cells</item><item key="VARIATION">depleted of EZH2</item></item></item><item><item key="GSM969462"><item key="TREATMENT PROTOCOL">under hormone depleted conditions</item><item key="CELL LINE">LNCaP-abl (abl) prostate cancer cells</item><item key="VARIATION">transfected with control siRNA</item></item></item><item><item key="GSM969463"><item key="TREATMENT PROTOCOL">under hormone depleted conditions</item><item key="CELL LINE">LNCaP-abl (abl) prostate cancer cells</item><item key="VARIATION">depleted of EZH2</item></item></item><item><item key="GSM969462"><item key="TREATMENT PROTOCOL">under hormone depleted conditions</item><item key="CELL LINE">LNCaP-abl (abl) prostate cancer cells</item><item key="VARIATION">transfected with control siRNA</item></item></item></item><item key="ownerprofile_id">arrayexpress_sid</item><item key="platform">4</item><item key="summary_wrapped">EZH2 is frequently over-expressed in aggressive and metastatic solid tumors, including castration resistant prostate cancer (CRPC). We...</item><item key="pubmed_id">23239736</item><item key="geo_gse_id">E-GEOD-39452</item><item key="owner_profile">/profile/8773/arrayexpressuploader</item><item key="factor_count">3</item><item key="sample_count">12</item><item key="tags"><item>androgen</item><item>cancer</item><item>cell</item><item>line</item><item>prostate</item><item>prostate cancer</item><item>solid</item></item><item key="lastmodified">Dec.12, 2014</item><item key="is_default">False</item><item key="geo_gds_id"/><item key="slug">expression-data-of-ezh2-dependent-genes-in-prostat</item><item key="geo_id_plat">E-GEOD-39452_A-AFFY-44</item><item key="name">Expression data of EZH2-dependent genes in prostate cancer cell lines</item><item key="created">Jul.12, 2014</item><item key="summary">EZH2 is frequently over-expressed in aggressive and metastatic solid tumors, including castration resistant prostate cancer (CRPC). We sought to determine EZH2-dependent gene expression programmes in prostate cancer progression, and found an intriguing functional switch of EZH2 from a repressor to an activator during CRPC development. We used microarrays to detail the global profiling of gene expression that are differentially regulated upon EZH2 depletion in two different prostate cancer cell lines. The androgen-dependent prostate cancer cell line LNCaP and the LNCaP-derived androgen-independent cell line LNCaP-abl (abl) were used for this study, as their transcription profiles strongly resemble that of clinical androgen-dependent and castration resistant prostate tumors, respectively. EZH2 was silenced by specific siRNAs in both cell lines, and total RNA was extracted and hybridized on Affymetrix microarrays.</item><item key="source">http://www.ebi.ac.uk/arrayexpress/experiments/E-GEOD-39452</item><item key="species">human</item><item key="sample_source">http://www.ebi.ac.uk/arrayexpress/experiments/E-GEOD-39452/samples/</item></data></biogps>
